<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Helicobacter pylori and gastroesophageal reflux disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Helicobacter pylori and gastroesophageal reflux disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Helicobacter pylori and gastroesophageal reflux disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John E Pandolfino, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Kahrilas, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Helicobacter pylori</em> (<em>H. pylori</em>) is an important risk factor for the development of peptic ulcer disease, gastric adenocarcinoma, and primary B cell lymphoma of the stomach. A possible role for <em>H. pylori</em> in the pathogenesis of gastroesophageal reflux disease (GERD) has also been suggested in a growing number of studies. However, the link between GERD and <em>H. pylori</em> is complex.</p><p>This topic review will summarize the available evidence suggesting a role for <em>H. pylori</em> in GERD. The pathophysiology of GERD and the treatment of <em>H. pylori</em> are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">"Pathophysiology of reflux esophagitis"</a> and  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Suspicion of an interaction between <em>H. pylori</em> and gastroesophageal reflux disease (GERD) stems from epidemiologic data showing that as the prevalence of <em>H. pylori</em> decreased in Western societies, the prevalence of GERD and adenocarcinoma of the esophagus increased [<a href="#rid1">1</a>]. This trend led several investigators to examine the prevalence of <em>H. pylori</em> in patients with GERD.</p><p>Several reports have suggested that <em>H. pylori</em>-positive patients were less likely to have GERD, and, when present, the severity of esophagitis was decreased compared with those who were <em>H. pylori</em> negative [<a href="#rid2">2-4</a>]. A lower prevalence of Barrett's metaplasia and esophageal adenocarcinoma has also been described in individuals who were <em>H. pylori</em> positive [<a href="#rid5">5,6</a>]. </p><p>Some studies suggested that <em>H. pylori</em> strains positive for Cag A (strains strongly associated with the development of corpus gastritis) may be particularly protective against the development of esophageal adenocarcinoma [<a href="#rid7">7-9</a>]. Thus, the available data suggest that colonization with <em>H. pylori</em>, particularly Cag A strains, may be protective against the more severe forms of GERD. Unfortunately, Cag A positive strains have also been associated with gastric adenocarcinoma. (See  <a class="medical medical_review" href="/z/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY OF GERD AS IT RELATES TO H. PYLORI</span><span class="headingEndMark"> — </span>Gastroesophageal reflux disease (GERD) is a clinical condition that results from the reflux of caustic fluid from the stomach into the esophagus. The pathophysiology of GERD is multifactorial with the disease ultimately related to the balance between factors tending to damage (or sensitize) the esophageal mucosa (excessive mucosal exposure time to caustic refluxate) and those tending to preserve it (a competent esophagogastric junction [EGJ] and normal esophageal acid clearance). GERD occurs when the balance is tipped in favor of the caustic factors. (See  <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">"Pathophysiology of reflux esophagitis"</a>.)</p><p>For <em>H. pylori</em> to exert a direct pathogenetic effect on GERD, it must have an impact on one of these primary disease determinants. However:</p><p class="bulletIndent1"><span class="glyph">●</span><em>H. pylori</em> has no apparent effect on EGJ competence [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no data suggesting that <em>H. pylori</em> decreases lower esophageal sphincter (LES) pressure or the frequency of transient LES relaxations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal peristaltic function and acid clearance are unlikely to be affected by <em>H. pylori</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There have been reports of <em>H. pylori</em> colonizing the esophageal mucosa. Whether such colonization affects mucosal sensitivity has not been determined.</p><p></p><p>The primary mechanism by which <em>H. pylori</em> might predispose to GERD is by modifying the gastric refluxate. However, the effects appear to be different in antral-dominant and corpus-dominant or pangastritis  (<a class="graphic graphic_figure graphicRef53651" href="/z/d/graphic/53651.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H4"><span class="h2">Antrum-dominant gastritis</span><span class="headingEndMark"> — </span><em>H. pylori</em> infection has a major effect on somatostatin secreting D cells in the gastric antrum such that feedback inhibition by luminal acid on gastrin release is interrupted. As a result, gastrin levels are higher in <em>H. pylori</em>-infected individuals [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/17.html" rel="external">"Association between Helicobacter pylori infection and duodenal ulcer"</a>.)</p><p>Thus, lack of feedback inhibition may be responsible for the increased acid secretion found in patients with duodenal ulcers who are <em>H. pylori</em> positive and have antral-dominant gastritis. Another theory suggests that eradication of <em>H. pylori</em> restores gastric bicarbonate secretion to levels seen in patients without <em>H. pylori</em> infection without affecting gastric acid secretion [<a href="#rid11">11</a>]. The net effect is the same — increased acidity of gastric secretions.</p><p class="headingAnchor" id="H5"><span class="h2">Corpus-dominant and pangastritis</span><span class="headingEndMark"> — </span><em>H. pylori</em> infection associated with corpus (fundus)-dominant gastritis is also associated with increased gastrin levels, but acid secretion is reduced. It has been proposed that corpus-dominant gastritis decreases acid secretion via local inflammation and increased levels of cytokines, such as tumor necrosis factor alpha and interleukin-1-beta. These changes can eventually lead to hypochlorhydria and gastric atrophy.</p><p>Reversal of <em>H. pylori</em>-induced corpus-dominant gastritis (and associated hypochlorhydria) has the potential to increase gastric acid secretion, which could render caustic what was previously asymptomatic reflux [<a href="#rid11">11</a>]. Return of acid secretion shortly after successful eradication of <em>H. pylori</em> has been associated with increased expression of H/K ATPase mRNA, not increased parietal cell number [<a href="#rid12">12</a>]. Whether return of parietal cell numbers increases acid secretion in the long-term is unclear.</p><p class="headingAnchor" id="H6"><span class="h1">H. PYLORI ERADICATION AND GASTROESOPHAGEAL REFLUX DISEASE</span><span class="headingEndMark"> — </span>Studies on the effect of <em>H. pylori</em> eradication and gastroesophageal reflux disease (GERD) have been conflicting. The disparities can be explained by an understanding of the variable effects of <em>H. pylori</em> on gastric acid secretion discussed above. Most of the initial studies failed to differentiate patients on the basis of gastritis severity or distribution. In addition, the period of observation in these studies may have been too short (approximately six months) to allow for physiological equilibration to occur. Bearing these limitations in mind, the following sections will summarize available data on the effect of <em>H. pylori</em> eradication on GERD in specific patient groups: duodenal ulcer, corpus-dominant gastritis, and GERD. (See  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Patients with duodenal ulcers</span><span class="headingEndMark"> — </span>Chronic <em>H. pylori</em> infection is the most important risk factor predisposing to duodenal ulcer disease. The lifetime prevalence of peptic ulcer disease in <em>H. pylori</em>-infected patients is approximately 5 to 10 percent. (See  <a class="medical medical_review" href="/z/d/html/17.html" rel="external">"Association between Helicobacter pylori infection and duodenal ulcer"</a>.)</p><p>Because antrum-dominant <em>H. pylori</em> gastritis is associated with increased gastric acid secretion, such patients should be at increased risk for developing GERD and duodenal ulcer disease, and both conditions should improve with <em>H. pylori</em> eradication. Several studies addressing this issue have produced variable results, which may in part be explained in differences in study populations and endpoints measured [<a href="#rid13">13-18</a>]. Considered together, they suggest a modest benefit of <em>H. pylori</em> eradication on GERD-symptoms in patients with duodenal ulcer disease and preexisting GERD. (See <a class="local">'Antrum-dominant gastritis'</a> above.)</p><p>The following illustrates the range of findings in the largest studies:</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of eight double-blind prospective trials of <em>H. pylori</em> therapy in a total of 1165 patients with duodenal ulcer disease (940 active, 225 past history) found that eradication of <em>H. pylori</em> did not lead to the development of erosive esophagitis or new symptomatic GERD, but may improve symptoms (heartburn, regurgitation) in patients with preexisting GERD [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar conclusions were reached in a systematic review of 27 studies, which found no evidence that <em>H. pylori</em> eradication in patients with duodenal ulcer disease provoked reflux esophagitis or worsened heartburn [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Patients with corpus-dominant or pangastritis</span><span class="headingEndMark"> — </span>Significant corpus gastritis can be associated with decreased acid secretion. In such patients, <em>H. pylori</em> eradication may result in increased acid secretion, which could be clinically relevant in patients predisposed to GERD. Several investigators have observed that GERD was less common in patients with severe corpus gastritis [<a href="#rid13">13,19,20</a>], while others have demonstrated that improvement of gastritis in these patients has been associated with an increased risk for the development of GERD [<a href="#rid21">21,22</a>].</p><p>It is important to emphasize again that <em>H. pylori</em> eradication does not cause GERD, it only unmasks it. Patients with impaired defense mechanisms, such as impaired esophageal acid clearance, hiatal hernia, and a hypotensive LES, are predisposed to GERD but may be protected by the decreased acid secretion induced by the inflammation and atrophy caused by <em>H. pylori</em> gastritis. This was demonstrated by a study evaluating risk factors for incident esophagitis after <em>H. pylori</em> eradication [<a href="#rid21">21</a>]; after eradication, the cumulative prevalence of esophagitis was significantly higher among those with a hiatus hernia (26 versus 8 percent), a known risk factor for GERD.</p><p class="headingAnchor" id="H9"><span class="h2">Patients with GERD</span><span class="headingEndMark"> — </span>Studying the effects <em>of H. pylori</em> eradication in patients with GERD is difficult because these patients necessarily have preserved acid secretion and EGJ compromise. Because they have preserved acid secretion, it is likely that these patients have either antral-dominant gastritis or only mild corpus gastritis. Regardless, eradication should not significantly worsen acid reflux in patients with preexisting GERD and should improve reflux in patients with antral-dominant gastritis. At least three studies support this hypothesis [<a href="#rid23">23-25</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Effect of H. pylori on PPI therapy</span><span class="headingEndMark"> — </span><em>H. pylori</em> infection affects gastric acid secretion in patients treated with proton pump inhibitors (PPIs). For example, inhibition of gastric acid secretion with a PPI is greater in patients with <em>H. pylori</em> infection compared to <em>H. pylori</em>-negative subjects [<a href="#rid26">26,27</a>]. Studies of patients with duodenal ulcers have also demonstrated that the acid suppressing ability of PPIs is augmented in patients who are infected with <em>H. pylori</em> [<a href="#rid26">26,28</a>]. </p><p>Whether or not the demonstrated effect of <em>H. pylori</em> on acid suppression with PPIs is clinically important has yet to be determined. In one study, PPIs appeared to be more effective in preventing and curing ulcers in patients who are <em>H. pylori</em> positive with or without NSAID use [<a href="#rid29">29</a>]. However, in a controlled trial comparing the efficacy of <a class="drug drug_general" data-topicid="9104" href="/z/d/drug information/9104.html" rel="external">esomeprazole</a> with <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">lansoprazole</a>, healing rates with PPIs were not influenced by <em>H. pylori</em> status [<a href="#rid30">30</a>]. In combined analysis of three large controlled trials of short- and long-term treatment in patients with reflux disease, <em>H. pylori</em> was a weak independent protective factor against relapse [<a href="#rid31">31</a>]. In another open-label study that included 971 patients with symptomatic reflux and esophagitis treated with <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">pantoprazole</a>, relief from heartburn and regurgitation and the likelihood of endoscopic healing after four weeks of therapy was significantly greater in <em>H. pylori</em>-positive patients compared with <em>H. pylori</em>-negative patients (87 versus 76 percent) [<a href="#rid32">32</a>]. Long-term studies evaluating maintenance therapy for GERD found no difference in the PPI dose required for <em>H. pylori</em>-negative and positive patients [<a href="#rid33">33,34</a>]. Thus, it appears that although <em>H. pylori</em> increases the acid suppressive effect of PPIs, there is no evidence suggesting a need to titrate the dose according to the presence of <em>H. pylori</em>.</p><p>Another issue that may be of clinical relevance is acid rebound after discontinuation of PPIs. Studies suggest that it may be more difficult to withdraw PPI therapy in <em>H. pylori</em> negative patients (see  <a class="medical medical_review" href="/z/d/html/33.html" rel="external">"Physiology of gastric acid secretion"</a>). The potential significance of this effect was illustrated in a study in which basal acid output increased by 82 percent in <em>H. pylori</em>-negative patients and decreased by 32 percent in <em>H. pylori</em>-positive patients at day 15 after <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a> therapy was discontinued [<a href="#rid35">35</a>]. The authors speculated that this phenomenon was the result of persistence of corpus gastritis in <em>H. pylori</em>-positive patients. </p><p class="headingAnchor" id="H11"><span class="h3">Theoretical risk of long-term PPI therapy</span><span class="headingEndMark"> — </span>A major concern regarding long-term PPI therapy has been the suggestion that patients infected by <em>H. pylori</em> are at increased risk for the development of atrophic gastritis during long-term therapy with PPIs [<a href="#rid36">36</a>]. A US Food and Drug Administration panel reviewing the data supporting this contention concluded that the findings were flawed and inconclusive. (See  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults"</a>.)</p><p>However, at least two controlled trials have demonstrated that eradication of <em>H. pylori</em> in patients with reflux esophagitis receiving long-term acid suppression therapy decreases inflammation and reverses corpus gastritis [<a href="#rid37">37,38</a>]. As a result, European consensus guidelines suggest that <em>H. pylori</em> testing be performed in patients receiving long-term acid suppression with PPIs [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H6803517"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15325.html" rel="external">"Patient education: Acid reflux and GERD in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15734.html" rel="external">"Patient education: H. pylori infection (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2011.html" rel="external">"Patient education: Gastroesophageal reflux disease in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2012.html" rel="external">"Patient education: Helicobacter pylori infection and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Eradication of <em>H. pylori</em> is associated with mild worsening of gastroesophageal reflux disease (GERD) in patients with corpus-dominant or pangastritis and improvement in those with antral-dominant gastritis. These effects must be balanced against the risks of continued infection  (<a class="graphic graphic_figure graphicRef53651" href="/z/d/graphic/53651.html" rel="external">figure 1</a>). (See <a class="local">'Pathophysiology of GERD as it relates to H. pylori'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <em>H. pylori</em> diagnosed in the context of peptic ulcer disease, eradication is the standard of care. Failure to eradicate <em>H. pylori</em> in the context of peptic ulcer disease is associated with a 60 to 100 percent annual ulcer recurrence rate compared with 10 percent after eradication. (See <a class="local">'Patients with duodenal ulcers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <em>H. pylori</em> diagnosed outside the context of peptic ulcer disease, most authorities would advocate eradication based upon a 10 percent lifetime risk of developing peptic ulcer disease and a two to three times higher incidence of gastric adenocarcinoma. The mild increase in reflux associated with eliminating corpus gastritis does not outweigh these risks. Similarly, the overall impact that <em>H. pylori</em> may have on the risk of esophageal adenocarcinoma is insignificant. (See <a class="local">'Corpus-dominant and pangastritis'</a> above and  <a class="medical medical_review" href="/z/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <em>H. pylori</em> diagnosed in the context of GERD, the available data do not demonstrate worsening disease with <em>H. pylori </em>eradication; in fact, GERD may be improved in individuals with antral-dominant gastritis. In addition, although <em>H. pylori</em> improves the ability of proton pump inhibitors to suppress acid, the dose required to maintain remission of esophagitis is not affected. (See <a class="local">'Patients with GERD'</a> above and <a class="local">'Effect of H. pylori on PPI therapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">el-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43:327.</a></li><li><a class="nounderline abstract_t">Hackelsberger A, Schultze V, Gunther T, et al. Helicobacter pylori prevalence in reflux esophagitis: A case control study (abstract). Gastroenterology 1997; 112:A137.</a></li><li><a class="nounderline abstract_t">Shirota T, Kusano M, Kawamura O, et al. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol 1999; 34:553.</a></li><li><a class="nounderline abstract_t">Chung SJ, Lim SH, Choi J, et al. Helicobacter pylori Serology Inversely Correlated With the Risk and Severity of Reflux Esophagitis in Helicobacter pylori Endemic Area: A Matched Case-Control Study of 5,616 Health Check-Up Koreans. J Neurogastroenterol Motil 2011; 17:267.</a></li><li><a class="nounderline abstract_t">Wang C, Yuan Y, Hunt RH. Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis. Am J Gastroenterol 2009; 104:492.</a></li><li><a class="nounderline abstract_t">Fischbach LA, Graham DY, Kramer JR, et al. Association between Helicobacter pylori and Barrett's esophagus: a case-control study. Am J Gastroenterol 2014; 109:357.</a></li><li><a class="nounderline abstract_t">Weston AP, Badr AS, Topalovski M, et al. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000; 95:387.</a></li><li><a class="nounderline abstract_t">Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115:50.</a></li><li><a class="nounderline abstract_t">Vaezi MF, Falk GW, Peek RM, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 2000; 95:2206.</a></li><li><a class="nounderline abstract_t">el-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109:681.</a></li><li><a class="nounderline abstract_t">Feldman M, Cryer B, Sammer D, et al. Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. Am J Physiol 1999; 277:G1159.</a></li><li><a class="nounderline abstract_t">Osawa H, Kita H, Ohnishi H, et al. Helicobacter pylori eradication induces marked increase in H+/K+-adenosine triphosphatase expression without altering parietal cell number in human gastric mucosa. Gut 2006; 55:152.</a></li><li><a class="nounderline abstract_t">Labenz J, Blum AL, Bayerdörffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112:1442.</a></li><li><a class="nounderline abstract_t">McColl KE, Dickson A, El-Nujumi A, et al. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95:101.</a></li><li><a class="nounderline abstract_t">Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14:45.</a></li><li><a class="nounderline abstract_t">Ishiki K, Mizuno M, Take S, et al. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease. Clin Gastroenterol Hepatol 2004; 2:474.</a></li><li><a class="nounderline abstract_t">Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97:2992.</a></li><li><a class="nounderline abstract_t">Raghunath AS, Hungin AP, Wooff D, Childs S. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004; 20:733.</a></li><li><a class="nounderline abstract_t">Wu JC, Sung JJ, Chan FK, et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14:427.</a></li><li><a class="nounderline abstract_t">Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 49:330.</a></li><li><a class="nounderline abstract_t">Hamada H, Haruma K, Mihara M, et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14:729.</a></li><li><a class="nounderline abstract_t">Iijima K, Ohara S, Sekine H, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut 2000; 46:20.</a></li><li><a class="nounderline abstract_t">Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999; 13:915.</a></li><li><a class="nounderline abstract_t">Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001; 357:1738.</a></li><li><a class="nounderline abstract_t">Moayyedi P, Bardhan C, Young L, et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121:1120.</a></li><li><a class="nounderline abstract_t">Verdú EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36:539.</a></li><li><a class="nounderline abstract_t">Giral A, Celikel CA, Ozdogan O, et al. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. J Gastroenterol Hepatol 2005; 20:1886.</a></li><li><a class="nounderline abstract_t">Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110:725.</a></li><li><a class="nounderline abstract_t">Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350:975.</a></li><li><a class="nounderline abstract_t">Vakil NB, Traxler BM, Levine D. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004; 99:1437.</a></li><li><a class="nounderline abstract_t">Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32:974.</a></li><li><a class="nounderline abstract_t">Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117:11.</a></li><li><a class="nounderline abstract_t">Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999; 94:884.</a></li><li><a class="nounderline abstract_t">Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118:661.</a></li><li><a class="nounderline abstract_t">Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116:239.</a></li><li><a class="nounderline abstract_t">Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334:1018.</a></li><li><a class="nounderline abstract_t">Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53:12.</a></li><li><a class="nounderline abstract_t">Yang HB, Sheu BS, Wang ST, et al. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol 2009; 104:1642.</a></li><li><a class="nounderline abstract_t">Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772.</a></li></ol></div><div id="topicVersionRevision">Topic 11 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9863476" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Opposing time trends of peptic ulcer and reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Helicobacter pylori prevalence in reflux esophagitis: A case control study (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10535481" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860818" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Helicobacter pylori Serology Inversely Correlated With the Risk and Severity of Reflux Esophagitis in Helicobacter pylori Endemic Area: A Matched Case-Control Study of 5,616 Health Check-Up Koreans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19174811" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419485" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Association between Helicobacter pylori and Barrett's esophagus: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10685740" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9649458" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007219" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657096" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10600812" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15872000" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Helicobacter pylori eradication induces marked increase in H+/K+-adenosine triphosphatase expression without altering parietal cell number in human gastric mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9136820" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10638566" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632644" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15181615" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12492181" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15379833" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10759622" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511552" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10848656" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601049" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383526" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The effect of Helicobacter pylori eradication on gastro-oesophageal reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11403809" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11677204" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7737560" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336449" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608881" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329511" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307856" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9361168" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10381904" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201451" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10734017" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922302" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598839" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14684569" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436275" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17170018" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
